Dexpanthenol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dexpanthenol: From Vitamin Supplementation to Anorectal Stricture
One-Sentence Summary
Dexpanthenol is a precursor of pantothenic acid (vitamin B5). In South Africa it is registered only as a component of the multivitamin infusion Cernevit. The TxGNN model predicts it may be effective for anorectal stricture. No clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Anorectal stricture |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
The registration data supplied no approved indication text, so the original indication is not listed here.
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available. Dexpanthenol is converted in the body to pantothenic acid, a precursor of coenzyme A. Coenzyme A is central to cellular energy metabolism, and pantothenate supports epithelial repair.
The link to anorectal stricture is speculative. A stricture is a fibrotic narrowing, and there is no evidence that supporting epithelial repair prevents or reverses fibrosis. The high score most likely reflects the drug’s position in the knowledge graph rather than a demonstrated effect.
The only registered product is an infusion. Treating an anorectal condition would probably need a topical or rectal formulation, and route compatibility has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 36/22.1/0508 | Cernevit | Infusion | Not stated in the data provided |
Essential Medicines List (EML) status was not included in the data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no trials, no literature, and only a speculative mechanism. Safety data from the SAHPRA package insert are also missing, which blocks safety screening.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications) for Cernevit
- Mechanism of action data, for example from DrugBank
- Any preclinical or clinical evidence on dexpanthenol in anorectal stricture
- A route and formulation assessment, since the registered product is an infusion
- For context, the only indication in this pack with trial evidence is exanthem (rank 6, L4). That evidence is indirect and comes from adjacent skin conditions, and it could be prioritised as a research question.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.